Patents by Inventor Victor E. Kotelianski

Victor E. Kotelianski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
    Publication number: 20210403917
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: February 26, 2021
    Publication date: December 30, 2021
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
    Publication number: 20200318119
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: November 5, 2019
    Publication date: October 8, 2020
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 10501742
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: December 10, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
    Publication number: 20180216115
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: November 8, 2017
    Publication date: August 2, 2018
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Method for the treatment of inflammatory disorders
    Patent number: 9902774
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: February 27, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Antonin De Fougerolles, Philip Gotwals, Roy R. Lobb, Victor E. Kotelianski
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 9822365
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: November 21, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
    Publication number: 20160348117
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: January 25, 2016
    Publication date: December 1, 2016
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20160185846
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: June 22, 2015
    Publication date: June 30, 2016
    Applicant: BIOGEN MA INC.
    Inventors: Antonin R. DE FOUGEROLLES, Victor E. KOTELIANSKI, Carl REID, Ellen GARBER
  • Antibodies against monocyte chemotactic proteins
    Patent number: 9096665
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: August 4, 2015
    Assignee: Biogen MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 8809292
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: August 19, 2014
    Assignee: Alnylam Pharmaceuticals, Inc
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20140178382
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: April 16, 2013
    Publication date: June 26, 2014
    Applicant: Biogen IDEC MA, Inc.
    Inventors: ANTONIN R. DE FOUGEROLLES, VICTOR E. KOTELIANSKI, CARL REID, ELLEN GARBER
  • METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20140154259
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Application
    Filed: September 9, 2013
    Publication date: June 5, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: ANTONIN DE FOUGEROLLES, Philip Gotwals, Roy R. Lobb, Victor E. Kotelianski
  • HUMANIZED ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20140079697
    Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Application
    Filed: July 2, 2013
    Publication date: March 20, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Antonin R. DE FOUGEROLLES, Victor E. KOTELIANSKI, Ellen GARBER, Carl REID, Jose W. SALDANHA, Herman VAN VLIJMEN
  • Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene
    Publication number: 20130331430
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene.
    Type: Application
    Filed: May 15, 2012
    Publication date: December 12, 2013
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Method for the treatment of inflammatory disorders
    Patent number: 8557240
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: October 15, 2013
    Assignee: Biogen IDEC MA Inc.
    Inventors: Philip Gotwals, Antonin de Fougerolles, Roy Lobb, Victor E. Kotelianski
  • Humanized antibodies against monocyte chemotactic proteins
    Patent number: 8519112
    Abstract: The invention provides humanized antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 27, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
  • Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins
    Patent number: 8431125
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 30, 2013
    Assignee: Biogen Idec MA, Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 8222222
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and methods for inhibiting expression of a PCSK9 gene in a cell.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: July 17, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20120039873
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: June 9, 2011
    Publication date: February 16, 2012
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene
    Publication number: 20120016009
    Abstract: This invention relates to optimized methods for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: September 26, 2011
    Publication date: January 19, 2012
    Inventors: Kevin Fitzgerald, Antonin de Fougerolles, Akin Akinc, Victor E. Kotelianski